BlinkLab Limited, founded by neuroscientists, has developed a smartphone-based diagnostic platform for neurodevelopmental conditions like autism and ADHD. The technology uses AI and machine learning for screening tests in children as young as 18 months, aiming for earlier detection and intervention. The company is pursuing FDA approval to facilitate broader use of its technology.